Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704691 · ClinicalTrials.gov registry record · Early Phase 1
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
A Early Phase 1 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT00704691 is a Early Phase 1 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants.
The verdict
NCT00704691, a Early Phase 1 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to: * assess the effectiveness of lenalidomide for the treatment of patients with relapsed and or refractory peripheral T-cell lymphomas; and, * assess the safety of lenalidomide. There are reports suggesting a therapeutic benefit of thalidomide in patients with refractory and/or relapsed Non-Hodgkin's Lymphoma's (NHL) which have led to the formal investigation of lenalidomide in the treatment of relapsed NHL's.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704691
The ClinicalTrials.gov registry entry for NCT00704691 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00704691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704691 about?
NCT00704691 is a clinical study titled "Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas". The purpose of this study is to: * assess the effectiveness of lenalidomide for the treatment of patients with relapsed and or refractory peripheral T-cell lymphomas; and, * assess the safety of lenalidomide. There are reports suggesting a therapeutic benefit of thalidomide in patients with refrac...
What is the current status of trial NCT00704691?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00704691?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00704691?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.